Department of Hematology, Hospital Germans Trias i Pujol, Institut Catala d'Oncologia, Badalona, Spain.
Leuk Lymphoma. 2010 Nov;51(11):2063-9. doi: 10.3109/10428194.2010.520772. Epub 2010 Oct 7.
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype in non-immunosuppressed and in human immunodeficiency virus (HIV)-positive patients. The prognosis of DLBCL with germinal center (GC) phenotype is better than that of the non-germinal center (non-GC) phenotype by immunohistochemical expression profile (IHC) in some studies but not in others. The frequency and the prognosis of these phenotypic subtypes in DLBCL related to HIV infection is not well known. The objectives of this study were to characterize the IHC by tissue microarray in 98 patients with DLBCL, 34 of whom were HIV-positive, and to evaluate their prognosis. Patients with HIV-related DLBCL with a non-GC pattern had poorer prognosis than patients with non-HIV-related DLBCL with the same pattern, but this difference disappeared when we considered only patients receiving HAART.
弥漫性大 B 细胞淋巴瘤(DLBCL)是非免疫抑制和人类免疫缺陷病毒(HIV)阳性患者中最常见的淋巴瘤亚型。在一些研究中,通过免疫组织化学表达谱(IHC),具有生发中心(GC)表型的 DLBCL 的预后优于非生发中心(non-GC)表型,但在其他研究中并非如此。在与 HIV 感染相关的 DLBCL 中,这些表型亚型的频率和预后尚不清楚。本研究的目的是通过组织微阵列分析 98 例 DLBCL 患者(其中 34 例为 HIV 阳性)的 IHC,并评估其预后。具有非 GC 模式的 HIV 相关 DLBCL 患者的预后比具有相同模式的非 HIV 相关 DLBCL 患者差,但当我们仅考虑接受高效抗逆转录病毒治疗(HAART)的患者时,这种差异就消失了。